Polyclonal T-lymphocyte population recognizing DNP-modified tumor peptide–MHC complexes

The polyclonal T-lymphocyte population recognizing DNP-modified tumor peptide–MHC complexes is a specialized group of immune effector cells generated through hapten-based immunotherapy (Berd et al., 1986, Cancer Research). This population arises when autologous tumor cells are chemically modified with dinitrophenyl (DNP), a hapten that increases the immunogenicity of tumor-associated antigens by creating 'altered-self' epitopes (Berd et al., 1991, Journal of Clinical Oncology). These DNP-modified proteins are processed and presented by Major Histocompatibility Complex (MHC) molecules on the surface of tumor cells or antigen-presenting cells. The resulting T-cell repertoire is polyclonal, consisting of various CD4+ and CD8+ clones that recognize the unique DNP-peptide-MHC configuration (Manne et al., 2002, Cancer Research). This immune response is designed to bypass the natural tolerance the immune system often has toward unmodified tumor cells. Clinically, this mechanism has been utilized in vaccines like M-Vax to treat metastatic melanoma, aiming to induce tumor regression and improve patient survival (Soengas & Lowe, 2003, Nature). The presence of these T cells is often correlated with a positive clinical response, typically measured by delayed-type hypersensitivity reactions. While highly specific to the modified tumor, the polyclonal nature ensures a broad attack against multiple tumor-derived peptides.

Other names

DNP-specific T-cellsDNP-reactive T-lymphocytesHapten-specific T-cellsDNP-modified tumor-reactive T-cellsDNP-modified tumor peptide–MHC complex-reactive T-cells

Induction of a polyclonal T-cell response against hapten-modified tumor antigens presented on MHC molecules.